GeoVax Labs, Inc. (GOVX)
USD 0.88
(-13.73%)
USD 0.88
(-13.73%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 6.02 Million USD | -57.32% |
| 2022 | 14.11 Million USD | -26.25% |
| 2021 | 19.13 Million USD | 312.31% |
| 2020 | 4.64 Million USD | 30.76% |
| 2019 | 3.54 Million USD | 0.63% |
| 2018 | 3.52 Million USD | 8.5% |
| 2017 | 3.24 Million USD | -20.78% |
| 2016 | 4.1 Million USD | 31.36% |
| 2015 | 3.12 Million USD | -13.75% |
| 2014 | 3.62 Million USD | -23.08% |
| 2013 | 4.7 Million USD | -1.85% |
| 2012 | 4.79 Million USD | -33.84% |
| 2011 | 7.24 Million USD | -8.89% |
| 2010 | 7.95 Million USD | 13.93% |
| 2009 | 6.98 Million USD | 4.05% |
| 2008 | 6.71 Million USD | 47.79% |
| 2007 | 4.54 Million USD | 200.91% |
| 2006 | 1.5 Million USD | 72.32% |
| 2005 | 875.81 Thousand USD | -43.46% |
| 2004 | 1.54 Million USD | 128.91% |
| 2003 | 676.64 Thousand USD | 0.0% |
| 2002 | - USD | -100.0% |
| 2001 | 13.07 Million USD | 137.17% |
| 2000 | 5.51 Million USD | 17.75% |
| 1999 | 4.68 Million USD | -3.43% |
| 1998 | 4.84 Million USD | 109.68% |
| 1997 | 2.31 Million USD | 113.36% |
| 1996 | 1.08 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 5.86 Million USD | -23.57% |
| 2024 Q2 | 5.33 Million USD | -8.54% |
| 2023 Q1 | 4.27 Million USD | -20.74% |
| 2023 FY | 26.66 Million USD | 89.01% |
| 2023 Q4 | 7.67 Million USD | -10.79% |
| 2023 Q3 | 8.59 Million USD | 39.18% |
| 2023 Q2 | 6.17 Million USD | 44.7% |
| 2022 Q4 | 5.38 Million USD | 35.69% |
| 2022 FY | 14.11 Million USD | -26.25% |
| 2022 Q1 | 2.5 Million USD | -81.96% |
| 2022 Q3 | 3.97 Million USD | 77.06% |
| 2022 Q2 | 2.24 Million USD | -10.64% |
| 2021 Q3 | 1.98 Million USD | 26.52% |
| 2021 Q4 | 13.9 Million USD | 601.82% |
| 2021 FY | 19.13 Million USD | 312.31% |
| 2021 Q1 | 1.67 Million USD | 5.4% |
| 2021 Q2 | 1.56 Million USD | -6.46% |
| 2020 Q4 | 1.58 Million USD | 86.52% |
| 2020 Q3 | 851.76 Thousand USD | -4.16% |
| 2020 Q2 | 888.71 Thousand USD | -32.23% |
| 2020 Q1 | 1.31 Million USD | 52.55% |
| 2020 FY | 4.64 Million USD | 30.76% |
| 2019 FY | 3.54 Million USD | 0.63% |
| 2019 Q4 | 859.58 Thousand USD | 13.23% |
| 2019 Q1 | 1.06 Million USD | 14.15% |
| 2019 Q2 | 863.87 Thousand USD | -18.94% |
| 2019 Q3 | 759.14 Thousand USD | -12.12% |
| 2018 Q3 | 1.01 Million USD | 39.0% |
| 2018 Q2 | 731.39 Thousand USD | -13.36% |
| 2018 Q1 | 844.22 Thousand USD | 21.19% |
| 2018 Q4 | 933.62 Thousand USD | -8.17% |
| 2018 FY | 3.52 Million USD | 8.5% |
| 2017 Q2 | 870 Thousand USD | 3.08% |
| 2017 FY | 3.24 Million USD | -20.78% |
| 2017 Q1 | 844 Thousand USD | -24.01% |
| 2017 Q4 | 696.62 Thousand USD | -16.9% |
| 2017 Q3 | 838.34 Thousand USD | -3.64% |
| 2016 Q2 | 742.39 Thousand USD | -44.8% |
| 2016 Q1 | 1.34 Million USD | 57.54% |
| 2016 Q4 | 1.11 Million USD | 22.78% |
| 2016 FY | 4.1 Million USD | 31.36% |
| 2016 Q3 | 904.64 Thousand USD | 21.86% |
| 2015 Q4 | 853.76 Thousand USD | 19.58% |
| 2015 FY | 3.12 Million USD | -13.75% |
| 2015 Q2 | 749.54 Thousand USD | -6.9% |
| 2015 Q1 | 805.07 Thousand USD | -29.84% |
| 2015 Q3 | 714 Thousand USD | -4.74% |
| 2014 FY | 3.62 Million USD | -23.08% |
| 2014 Q4 | 1.14 Million USD | 37.05% |
| 2014 Q3 | 837.31 Thousand USD | -2.76% |
| 2014 Q2 | 861.06 Thousand USD | 11.15% |
| 2014 Q1 | 774.66 Thousand USD | -26.05% |
| 2013 Q3 | 1.19 Million USD | 23.38% |
| 2013 Q4 | 1.04 Million USD | -12.38% |
| 2013 FY | 4.7 Million USD | -1.85% |
| 2013 Q1 | 1.49 Million USD | 39.64% |
| 2013 Q2 | 968.98 Thousand USD | -35.18% |
| 2012 Q1 | 1.58 Million USD | -24.89% |
| 2012 FY | 4.79 Million USD | -33.84% |
| 2012 Q4 | 1.07 Million USD | 14.39% |
| 2012 Q2 | 1.2 Million USD | -24.0% |
| 2012 Q3 | 935.85 Thousand USD | -22.32% |
| 2011 FY | 7.24 Million USD | -8.89% |
| 2011 Q3 | 1.67 Million USD | -14.84% |
| 2011 Q2 | 1.96 Million USD | 30.96% |
| 2011 Q1 | 1.5 Million USD | 5.09% |
| 2011 Q4 | 2.11 Million USD | 26.13% |
| 2010 Q3 | 1.81 Million USD | -32.31% |
| 2010 FY | 7.95 Million USD | 13.93% |
| 2010 Q4 | 1.42 Million USD | -21.24% |
| 2010 Q1 | 2.03 Million USD | 63.12% |
| 2010 Q2 | 2.67 Million USD | 31.39% |
| 2009 Q3 | 2.04 Million USD | -3.07% |
| 2009 Q4 | 1.24 Million USD | -38.88% |
| 2009 FY | 6.98 Million USD | 4.05% |
| 2009 Q1 | 1.58 Million USD | -4.99% |
| 2009 Q2 | 2.1 Million USD | 33.39% |
| 2008 Q4 | 1.66 Million USD | -19.28% |
| 2008 Q3 | 2.06 Million USD | 22.93% |
| 2008 Q2 | 1.67 Million USD | 28.09% |
| 2008 Q1 | 1.3 Million USD | -6.7% |
| 2008 FY | 6.71 Million USD | 47.79% |
| 2007 Q2 | 1.35 Million USD | 120.93% |
| 2007 Q3 | 1.17 Million USD | -13.06% |
| 2007 Q1 | 611.72 Thousand USD | 30.63% |
| 2007 FY | 4.54 Million USD | 200.91% |
| 2007 Q4 | 1.4 Million USD | 19.41% |
| 2006 FY | 1.5 Million USD | 72.32% |
| 2006 Q4 | 468.27 Thousand USD | 51.38% |
| 2006 Q1 | 319.15 Thousand USD | 163.3% |
| 2006 Q2 | 337.93 Thousand USD | 5.88% |
| 2006 Q3 | 309.33 Thousand USD | -8.46% |
| 2005 Q1 | -207.43 Thousand USD | 69.78% |
| 2005 FY | 875.81 Thousand USD | -43.46% |
| 2005 Q2 | -435.22 Thousand USD | -109.82% |
| 2005 Q3 | -261.69 Thousand USD | 39.87% |
| 2005 Q4 | -504.18 Thousand USD | -92.66% |
| 2004 Q4 | -686.46 Thousand USD | -12.46% |
| 2004 Q1 | -1.01 Million USD | 0.0% |
| 2004 Q3 | -610.38 Thousand USD | 39.64% |
| 2004 FY | 1.54 Million USD | 128.91% |
| 2004 Q2 | -1.01 Million USD | 0.0% |
| 2003 FY | 676.64 Thousand USD | 0.0% |
| 2002 Q1 | 1.35 Million USD | -83.92% |
| 2002 Q2 | 1.27 Million USD | -5.7% |
| 2002 FY | - USD | -100.0% |
| 2002 Q4 | 4.53 Million USD | 266.59% |
| 2002 Q3 | 1.23 Million USD | -2.89% |
| 2001 Q3 | 1.54 Million USD | -19.34% |
| 2001 Q2 | 1.91 Million USD | 57.91% |
| 2001 FY | 13.07 Million USD | 137.17% |
| 2001 Q1 | 1.21 Million USD | 114.13% |
| 2001 Q4 | 8.4 Million USD | 443.7% |
| 2000 FY | 5.51 Million USD | 17.75% |
| 2000 Q4 | 566.71 Thousand USD | -80.3% |
| 2000 Q3 | 2.87 Million USD | 222.19% |
| 2000 Q2 | 893 Thousand USD | -24.19% |
| 2000 Q1 | 1.17 Million USD | 0.0% |
| 1999 FY | 4.68 Million USD | -3.43% |
| 1998 FY | 4.84 Million USD | 109.68% |
| 1997 FY | 2.31 Million USD | 113.36% |
| 1996 FY | 1.08 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AbCellera Biologics Inc. | 275.23 Million USD | 97.812% |
| Alkermes plc | 996.24 Million USD | 99.396% |
| Agenus Inc. | 78.18 Million USD | 92.297% |
| Aptorum Group Limited | 10.56 Thousand USD | -56895.769% |
| Ardelyx, Inc. | 169.93 Million USD | 96.456% |
| Dyadic International, Inc. | 9.15 Million USD | 34.203% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | 72.938% |
| Lantern Pharma Inc. | 17.87 Million USD | 66.314% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | 10.543% |
| Novavax, Inc. | 779.12 Million USD | 99.227% |
| Janux Therapeutics, Inc. | 81.06 Million USD | 92.571% |
| Pyxis Oncology, Inc. | 82.19 Million USD | 92.673% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | 68.987% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | 79.659% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | 88.664% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 98.417% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | 75.224% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | 84.097% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | 80.429% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | 92.891% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 65.503% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | 96.425% |
| Clearside Biomedical, Inc. | 32.71 Million USD | 81.592% |
| C4 Therapeutics, Inc. | 159.78 Million USD | 96.231% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 99.665% |
| AlloVir, Inc. | 180.93 Million USD | 96.672% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 98.649% |
| VYNE Therapeutics Inc. | 29.68 Million USD | 79.711% |
| Bicycle Therapeutics plc | 216.92 Million USD | 97.224% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | 96.497% |
| ChromaDex Corporation | 56.37 Million USD | 89.318% |
| Chimerix, Inc. | 93.38 Million USD | 93.552% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | 56.705% |
| Caribou Biosciences, Inc. | 150.53 Million USD | 96.0% |
| CRISPR Therapeutics AG | 463.49 Million USD | 98.701% |
| Precision BioSciences, Inc. | 92.46 Million USD | 93.487% |
| Fate Therapeutics, Inc. | 254.04 Million USD | 97.629% |
| Fortress Biotech, Inc. | 200.19 Million USD | 96.992% |
| Fortress Biotech, Inc. | 200.19 Million USD | 96.992% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | 81.609% |
| ImmuCell Corporation | 9.61 Million USD | 37.382% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | 96.184% |
| Immix Biopharma, Inc. | 16.14 Million USD | 62.69% |
| Incyte Corporation | 1.19 Billion USD | 99.494% |
| Innoviva, Inc. | 132.15 Million USD | 95.443% |
| IO Biotech, Inc. | 91.44 Million USD | 93.414% |
| Jaguar Health, Inc. | 42.01 Million USD | 85.667% |
| Keros Therapeutics, Inc. | 169.27 Million USD | 96.442% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | 92.858% |
| ContextLogic Inc. | 387 Million USD | 98.444% |
| MiMedx Group, Inc. | 229.72 Million USD | 97.379% |
| MEI Pharma, Inc. | 34.78 Million USD | 82.687% |
| NextCure, Inc. | 67.63 Million USD | 91.096% |
| Onconetix, Inc. | 34.9 Million USD | 82.748% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | 52.752% |
| Opthea Limited | 191.96 Million USD | 96.863% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -118.862% |
| Vaxcyte, Inc. | 468.04 Million USD | 98.713% |
| PDS Biotechnology Corporation | 43.04 Million USD | 86.01% |
| Precigen, Inc. | 84.18 Million USD | 92.846% |
| Pharming Group N.V. | 225.49 Million USD | 97.329% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | 96.412% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | 91.701% |
| PureTech Health plc | 144.59 Million USD | 95.835% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | 95.377% |
| Avidity Biosciences, Inc. | 245.15 Million USD | 97.544% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | 75.224% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 97.367% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | 80.485% |
| Acelyrin, Inc. | 422.06 Million USD | 98.573% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -46605.235% |
| Summit Therapeutics Inc. | 87.68 Million USD | 93.132% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | 83.752% |
| Senti Biosciences, Inc. | 94.7 Million USD | 93.641% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | 95.126% |
| Elevation Oncology, Inc. | 45.44 Million USD | 86.748% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | 79.564% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -52.768% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | 95.444% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | 82.332% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | 28.74% |
| Wave Life Sciences Ltd. | 181.3 Million USD | 96.678% |
| Seer, Inc. | 110.49 Million USD | 94.55% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | 91.469% |
| Aadi Bioscience, Inc. | 93.47 Million USD | 93.558% |
| ESSA Pharma Inc. | 32.13 Million USD | 81.259% |
| GlycoMimetics, Inc. | 39.28 Million USD | 84.671% |
| GT Biopharma, Inc. | 13.57 Million USD | 55.641% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | 97.261% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | 97.006% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | 97.679% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | 89.39% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | 88.864% |
| Alzamend Neuro, Inc. | 9.93 Million USD | 39.4% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 98.508% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | 68.185% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | 88.12% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | 97.681% |
| Aptose Biosciences Inc. | 52.35 Million USD | 88.498% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | 58.209% |
| Soligenix, Inc. | 7.79 Million USD | 22.746% |
| Century Therapeutics, Inc. | 56.07 Million USD | 89.26% |
| Kura Oncology, Inc. | 165.8 Million USD | 96.368% |
| TScan Therapeutics, Inc. | 114.5 Million USD | 94.741% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | 27.609% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -142.669% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | 94.408% |
| Autolus Therapeutics plc | 196.72 Million USD | 96.939% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | 92.886% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | 94.829% |
| Eterna Therapeutics Inc. | 19.38 Million USD | 68.931% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | 98.128% |
| GRI Bio, Inc. | 11.33 Million USD | 46.848% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | 14.648% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | 95.41% |
| IGM Biosciences, Inc. | 265.59 Million USD | 97.733% |
| INmune Bio, Inc. | 29.89 Million USD | 79.856% |
| Heron Therapeutics, Inc. | 172.55 Million USD | 96.51% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | 85.062% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | 62.313% |
| Entero Therapeutics, Inc. | 15.74 Million USD | 61.743% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | 90.302% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | 94.399% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 97.816% |
| Coherus BioSciences, Inc. | 301.45 Million USD | 98.002% |
| Verastem, Inc. | 92.08 Million USD | 93.46% |
| Abeona Therapeutics Inc. | 17.93 Million USD | 66.43% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | 96.757% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | 95.04% |
| Histogen Inc. | 14.27 Million USD | 57.804% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | 62.474% |
| Surrozen, Inc. | 18.55 Million USD | 67.535% |
| Organovo Holdings, Inc. | 14.91 Million USD | 59.623% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -18.308% |
| Ovid Therapeutics Inc. | 59.67 Million USD | 89.908% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | 76.519% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | 87.189% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | 21.102% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | 96.619% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | 87.57% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | 97.542% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | 60.81% |
| Apollomics, Inc. | 54.14 Million USD | 88.877% |
| Amarin Corporation plc | 272.35 Million USD | 97.789% |
| Mesoblast Limited | 5.9 Million USD | -2.036% |
| Turnstone Biologics Corp. | 78.33 Million USD | 92.313% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | 97.533% |
| Synaptogenix, Inc. | 8.31 Million USD | 27.565% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | 58.713% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | 97.62% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | 81.932% |
| Monopar Therapeutics Inc. | 8.83 Million USD | 31.808% |
| Exelixis, Inc. | 1.58 Billion USD | 99.62% |
| Better Therapeutics, Inc. | 38.26 Million USD | 84.261% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | 97.405% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 99.296% |
| NLS Pharmaceutics AG | 11.8 Million USD | 48.995% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | 25.115% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | 79.921% |
| Gritstone bio, Inc. | 148.37 Million USD | 95.941% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | 91.255% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | 63.19% |
| Avid Bioservices, Inc. | 25.99 Million USD | 76.834% |
| Insmed Incorporated | 949.26 Million USD | 99.366% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | 61.617% |
| MediWound Ltd. | 18.86 Million USD | 68.083% |
| OmniAb, Inc. | 83.89 Million USD | 92.822% |
| Alector, Inc. | 248.8 Million USD | 97.58% |
| Seres Therapeutics, Inc. | 234.3 Million USD | 97.43% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | 88.475% |
| Zai Lab Limited | 547.47 Million USD | 98.9% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 98.489% |
| Aura Biosciences, Inc. | 84.99 Million USD | 92.914% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | 97.563% |
| Immunic, Inc. | 99.22 Million USD | 93.931% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | 96.213% |
| Veracyte, Inc. | 357.93 Million USD | 98.318% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 99.933% |
| FibroGen, Inc. | 398.11 Million USD | 98.487% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | 57.62% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | 12.569% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | 15.487% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 99.815% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | 76.724% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | 98.098% |
| TG Therapeutics, Inc. | 198.47 Million USD | 96.966% |
| Galecto, Inc. | 35.62 Million USD | 83.097% |
| Calithera Biosciences, Inc. | 40.68 Million USD | 85.2% |
| Fortrea Holdings Inc. | 457.3 Million USD | 98.683% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | 88.905% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | 79.146% |
| XBiotech Inc. | 37.51 Million USD | 83.945% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | 91.255% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | 70.836% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | 95.761% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | 93.922% |
| Theravance Biopharma, Inc. | 110.71 Million USD | 94.561% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 99.372% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | 79.122% |
| Vaxxinity, Inc. | 56.05 Million USD | 89.256% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 98.602% |
| Gain Therapeutics, Inc. | 22.3 Million USD | 73.005% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | 94.568% |
| NexImmune, Inc. | 28.16 Million USD | 78.62% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -8.881% |
| Marker Therapeutics, Inc. | 17.89 Million USD | 66.342% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 99.786% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | 76.346% |
| Scopus BioPharma Inc. | 11.71 Million USD | 48.594% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | 95.26% |
| Ainos, Inc. | 12.95 Million USD | 53.506% |
| Pluri Inc. | 22.48 Million USD | 73.211% |
| Prothena Corporation plc | 282.4 Million USD | 97.868% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | 96.989% |
| Celularity Inc. | 215.05 Million USD | 97.2% |
| Rallybio Corporation | 78.93 Million USD | 92.37% |
| Cue Biopharma, Inc. | 19.54 Million USD | 69.183% |
| MeiraGTx Holdings plc | 151.07 Million USD | 96.014% |
| Omeros Corporation | 94.75 Million USD | 93.644% |
| Humacyte, Inc. | 23.49 Million USD | 74.37% |
| Immunocore Holdings plc | 308.04 Million USD | 98.045% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -77.645% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | 93.067% |
| Blueprint Medicines Corporation | 722.86 Million USD | 99.167% |
| CalciMedica, Inc. | 21.81 Million USD | 72.397% |
| Cabaletta Bio, Inc. | 74.66 Million USD | 91.934% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | 96.249% |
| Scholar Rock Holding Corporation | 171.29 Million USD | 96.484% |
| Sana Biotechnology, Inc. | 294.94 Million USD | 97.958% |
| Pulmatrix, Inc. | 22.03 Million USD | 72.674% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | 82.582% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | 93.223% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 98.908% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | 91.699% |
| Cytokinetics, Incorporated | 173.61 Million USD | 96.531% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | 82.503% |
| Nutriband Inc. | 5.73 Million USD | -5.025% |
| Protara Therapeutics, Inc. | 43.61 Million USD | 86.192% |
| Vor Biopharma Inc. | 126.03 Million USD | 95.222% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 99.494% |
| Evogene Ltd. | 27.79 Million USD | 78.33% |
| ProKidney Corp. | 151.52 Million USD | 96.026% |
| Applied Therapeutics, Inc. | 74.17 Million USD | 91.881% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | 21.711% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 99.02% |
| CorMedix Inc. | 48.95 Million USD | 87.699% |
| BioLineRx Ltd. | 50.8 Million USD | 88.146% |
| Tango Therapeutics, Inc. | 150.7 Million USD | 96.004% |
| Galectin Therapeutics Inc. | 38.07 Million USD | 84.182% |
| Atai Life Sciences N.V. | 125.78 Million USD | 95.212% |
| Renovaro Biosciences Inc. | 81.63 Million USD | 92.623% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | 92.603% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | 97.615% |
| Sagimet Biosciences Inc. | 32.74 Million USD | 81.606% |
| MediciNova, Inc. | 10.9 Million USD | 44.752% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | 95.325% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | 17.045% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 98.736% |
| Biomea Fusion, Inc. | 126.13 Million USD | 95.226% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 99.541% |
| Mereo BioPharma Group plc | 35.84 Million USD | 83.198% |
| Cullinan Oncology, Inc. | 191.08 Million USD | 96.848% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | 97.381% |
| Absci Corporation | 73.66 Million USD | 91.825% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | 78.166% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | 95.492% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | 97.513% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | 97.702% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | 97.105% |
| Allakos Inc. | 196.05 Million USD | 96.928% |
| Imunon, Inc. | 20.31 Million USD | 70.349% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | 94.693% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 98.366% |
| BioAtla, Inc. | 129.68 Million USD | 95.356% |
| NLS Pharmaceutics AG | 11.8 Million USD | 48.995% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | 61.988% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | 92.908% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | 85.578% |
| XOMA Corporation | 46.46 Million USD | 87.039% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | 94.583% |
| Cara Therapeutics, Inc. | 142.46 Million USD | 95.773% |
| aTyr Pharma, Inc. | 12.97 Million USD | 53.601% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | 94.19% |
| Akero Therapeutics, Inc. | 172.87 Million USD | 96.516% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | 97.636% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | 83.901% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | 26.78% |
| Akari Therapeutics, Plc | 16.8 Million USD | 64.167% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -164.831% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 97.988% |
| Lexaria Bioscience Corp. | 6.72 Million USD | 10.501% |
| UroGen Pharma Ltd. | 138.88 Million USD | 95.664% |
| Sutro Biopharma, Inc. | 243 Million USD | 97.522% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | 17.217% |
| Orgenesis Inc. | 45.75 Million USD | 86.839% |
| Entera Bio Ltd. | 8.86 Million USD | 32.03% |
| GH Research PLC | 41.22 Million USD | 85.391% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | 76.575% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | 92.749% |
| Xencor, Inc. | 306.97 Million USD | 98.038% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -22.064% |
| Replimune Group, Inc. | 234.77 Million USD | 97.435% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | 70.609% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | 96.86% |
| Lexaria Bioscience Corp. | 6.72 Million USD | 10.501% |
| Portage Biotech Inc. | 18.19 Million USD | 66.909% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | 17.045% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | 94.262% |
| OncoCyte Corporation | 25.63 Million USD | 76.51% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | 1.205% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | 47.437% |
| Purple Biotech Ltd. | -22.46 Million USD | 126.805% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | 63.458% |
| scPharmaceuticals Inc. | 65.17 Million USD | 90.76% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | 28.755% |
| HilleVax, Inc. | 133.34 Million USD | 95.484% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | 41.447% |
| Tharimmune, Inc. | 9.45 Million USD | 36.308% |
| Genprex, Inc. | 31.06 Million USD | 80.612% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | 96.789% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | 80.807% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -687.212% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -10.561% |
| OKYO Pharma Limited | 8243.57 USD | -72952.973% |
| Savara Inc. | 15.74 Million USD | 61.752% |
| Curis, Inc. | 58.35 Million USD | 89.68% |
| Daré Bioscience, Inc. | 33.6 Million USD | 82.082% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -18.256% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | 19.285% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | 77.714% |
| BeiGene, Ltd. | 3.28 Billion USD | 99.817% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | 69.797% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 98.793% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | 96.081% |
| Erasca, Inc. | 141.52 Million USD | 95.745% |
| bluebird bio, Inc. | 240.23 Million USD | 97.493% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -33.029% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 99.655% |
| DBV Technologies S.A. | 92.16 Million USD | 93.466% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -33.029% |
| Moderna, Inc. | 6.39 Billion USD | 99.906% |
| Vincerx Pharma, Inc. | 42.6 Million USD | 85.866% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | 58.08% |
| Molecular Templates, Inc. | 63.09 Million USD | 90.455% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | 90.971% |
| Travere Therapeutics, Inc. | 472 Million USD | 98.724% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | 95.798% |
| Spruce Biosciences, Inc. | 62.08 Million USD | 90.3% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | 86.129% |
| Cogent Biosciences, Inc. | 208.13 Million USD | 97.107% |
| MacroGenics, Inc. | 217.21 Million USD | 97.228% |
| RenovoRx, Inc. | 11.39 Million USD | 47.155% |
| Adicet Bio, Inc. | 152.03 Million USD | 96.039% |
| Prime Medicine, Inc. | 186.63 Million USD | 96.773% |
| Aditxt, Inc. | 25.95 Million USD | 76.794% |
| Adagene Inc. | 41.83 Million USD | 85.604% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | 17.618% |
| Quantum-Si incorporated | 111.65 Million USD | 94.607% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | 96.496% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | 58.689% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | 83.189% |
| SciSparc Ltd. | 9.01 Million USD | 33.169% |
| Vericel Corporation | 142.04 Million USD | 95.76% |
| Revelation Biosciences, Inc. | 8.65 Million USD | 30.433% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | 73.917% |
| Generation Bio Co. | 144.46 Million USD | 95.831% |
| Astria Therapeutics, Inc. | 83.03 Million USD | 92.747% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | 93.035% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | 97.964% |
| Invivyd, Inc. | 205.75 Million USD | 97.073% |
| Relay Therapeutics, Inc. | 72.15 Million USD | 91.654% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | 35.787% |
| Spero Therapeutics, Inc. | 75.25 Million USD | 91.998% |
| Artelo Biosciences, Inc. | 10.28 Million USD | 41.458% |
| 2seventy bio, Inc. | 289.88 Million USD | 97.923% |
| ADMA Biologics, Inc. | 66.58 Million USD | 90.956% |
| Clene Inc. | 41.07 Million USD | 85.338% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | 52.981% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | 89.01% |
| GeoVax Labs, Inc. | 6.02 Million USD | 0.0% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | 98.289% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | 83.605% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | 82.145% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | 94.193% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | 81.521% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | 96.463% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 99.216% |
| Evaxion Biotech A/S | 22.27 Million USD | 72.958% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | 95.557% |
| Verve Therapeutics, Inc. | 234.88 Million USD | 97.436% |
| Trevena, Inc. | 38.41 Million USD | 84.323% |
| Surrozen, Inc. | 18.55 Million USD | 67.535% |
| Tyra Biosciences, Inc. | 79.94 Million USD | 92.467% |
| Cingulate Inc. | 22.75 Million USD | 73.54% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 180.381% |
| Unity Biotechnology, Inc. | 44.66 Million USD | 86.518% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | 26.862% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | 94.128% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 99.201% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | 90.298% |
| Clearmind Medicine Inc. | 8.74 Million USD | 31.107% |
| Kronos Bio, Inc. | 128.11 Million USD | 95.3% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | 92.837% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -105.326% |
| Viking Therapeutics, Inc. | 100.82 Million USD | 94.027% |
| Statera Biopharma, Inc. | 28.82 Million USD | 79.111% |
| ImmunityBio, Inc. | 362.87 Million USD | 98.34% |
| Korro Bio, Inc. | 84.53 Million USD | 92.876% |
| Kineta, Inc. | 21.15 Million USD | 71.534% |
| BioVie Inc. | 31.95 Million USD | 81.151% |
| Codexis, Inc. | 66.51 Million USD | 90.947% |
| Celularity Inc. | 215.05 Million USD | 97.2% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | 97.343% |
| Celcuity Inc. | 66.23 Million USD | 90.907% |
| Virax Biolabs Group Limited | 6.54 Million USD | 8.017% |
| Cibus, Inc. | 320.3 Million USD | 98.12% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | 85.995% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | 82.206% |
| IN8bio, Inc. | 30.33 Million USD | 80.149% |
| Kodiak Sciences Inc. | 277.32 Million USD | 97.828% |
| Annexon, Inc. | 143.72 Million USD | 95.81% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | 95.28% |
| Assembly Biosciences, Inc. | 22.9 Million USD | 73.713% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -840.965% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 99.228% |
| Eyenovia, Inc. | 25.4 Million USD | 76.297% |
| Puma Biotechnology, Inc. | 140.31 Million USD | 95.708% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -8.274% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | 92.39% |
| Arcellx, Inc. | 200.19 Million USD | 96.992% |
| Cardiff Oncology, Inc. | 45.9 Million USD | 86.88% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | 97.217% |
| Regulus Therapeutics Inc. | 9.95 Million USD | 39.518% |
| Moolec Science SA | 52.75 Million USD | 88.584% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | 90.15% |
| Geron Corporation | 70.44 Million USD | 91.451% |
| LAVA Therapeutics N.V. | 46.54 Million USD | 87.06% |
| Royalty Pharma plc | 862.4 Million USD | 99.302% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | 93.598% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | 35.439% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | 73.387% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | 97.102% |
| Humacyte, Inc. | 23.49 Million USD | 74.37% |
| Structure Therapeutics Inc. | 102.77 Million USD | 94.14% |
| 89bio, Inc. | 151.2 Million USD | 96.017% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | 92.485% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | 58.582% |
| Genelux Corporation | 24.33 Million USD | 75.253% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | 82.248% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | 96.516% |
| Notable Labs, Ltd. | 14.77 Million USD | 59.227% |
| Liquidia Corporation | 87.98 Million USD | 93.155% |
| Mustang Bio, Inc. | 48.5 Million USD | 87.583% |
| Immunovant, Inc. | 282.7 Million USD | 97.87% |
| Quantum-Si incorporated | 111.65 Million USD | 94.607% |
| Arbutus Biopharma Corporation | 22.54 Million USD | 73.287% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | 71.683% |
| Vera Therapeutics, Inc. | 102.01 Million USD | 94.097% |
| Acasti Pharma Inc. | 11.3 Million USD | 46.711% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | 73.727% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | 62.313% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | 87.061% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -430.784% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | 62.091% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | 79.346% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | 85.448% |
| PepGen Inc. | 84.76 Million USD | 92.896% |
| Moleculin Biotech, Inc. | 29.63 Million USD | 79.676% |
| United Therapeutics Corporation | 885.1 Million USD | 99.32% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | 73.699% |
| Solid Biosciences Inc. | 104.31 Million USD | 94.227% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | 81.598% |
| Immuneering Corporation | 58.41 Million USD | 89.69% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -18.308% |
| Silo Pharma, Inc. | 3.92 Million USD | -53.554% |
| Belite Bio, Inc | 31.66 Million USD | 80.983% |
| XOMA Corporation | 46.46 Million USD | 87.039% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | 91.085% |
| Bionomics Limited | 17.89 Billion USD | 99.966% |
| Apogee Therapeutics, Inc. | 93 Million USD | 93.525% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 116.878% |
| uniQure N.V. | 285.08 Million USD | 97.888% |
| Cassava Sciences, Inc. | 105.95 Million USD | 94.316% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | 17.618% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | 96.899% |
| Forte Biosciences, Inc. | 32.47 Million USD | 81.457% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | 27.52% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | 79.513% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -8.274% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | 57.62% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | 32.251% |
| Altimmune, Inc. | 30.55 Million USD | 80.291% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 98.592% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 116.878% |
| Compugen Ltd. | 43.97 Million USD | 86.304% |
| Peak Bio, Inc. | 1249.13 USD | -482009.388% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | 91.875% |
| Benitec Biopharma Inc. | 22.38 Million USD | 73.094% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | 97.524% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | 78.901% |
| Zura Bio Limited | 62.63 Million USD | 90.386% |
| PolyPid Ltd. | 21.04 Million USD | 71.384% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | 63.0% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | 78.901% |
| Instil Bio, Inc. | 85.78 Million USD | 92.98% |
| argenx SE | 1.53 Billion USD | 99.607% |
| Immunome, Inc. | 122.82 Million USD | 95.097% |
| Compass Therapeutics, Inc. | 48.47 Million USD | 87.576% |
| Verona Pharma plc | 67.15 Million USD | 91.032% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | 76.735% |
| Shattuck Labs, Inc. | 93.61 Million USD | 93.567% |
| CervoMed Inc. | 14.95 Million USD | 59.739% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | 91.482% |
| Plus Therapeutics, Inc. | 8.54 Million USD | 29.516% |
| Dianthus Therapeutics, Inc. | 51 Million USD | 88.192% |
| Moolec Science SA | 52.75 Million USD | 88.584% |
| Enveric Biosciences, Inc. | 16.44 Million USD | 63.388% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | 95.457% |
| AnaptysBio, Inc. | 181.56 Million USD | 96.683% |
| Design Therapeutics, Inc. | 78.19 Million USD | 92.298% |
| Leap Therapeutics, Inc. | 87.04 Million USD | 93.081% |
| NeurAxis, Inc. | 8.82 Million USD | 31.731% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | 52.148% |
| Lumos Pharma, Inc. | 38.66 Million USD | 84.425% |
| Achilles Therapeutics plc | 75.25 Million USD | 91.998% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | 76.735% |
| 180 Life Sciences Corp. | 13.47 Million USD | 55.317% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | 77.277% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -105.326% |
| Nutriband Inc. | 5.73 Million USD | -5.025% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | 94.564% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | 89.179% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | 88.164% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | 90.889% |
| MoonLake Immunotherapeutics | 54.12 Million USD | 88.873% |
| Palisade Bio, Inc. | 13.32 Million USD | 54.788% |
| Tourmaline Bio, Inc. | 45.4 Million USD | 86.738% |
| Beam Therapeutics Inc. | 554.19 Million USD | 98.913% |
| Neurogene Inc. | 55.58 Million USD | 89.165% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | 97.576% |
| AEON Biopharma, Inc. | 48.42 Million USD | 87.565% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | 93.773% |
| Sesen Bio, Inc. | 78.38 Million USD | 92.317% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | 92.79% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | 52.155% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 98.665% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | 93.148% |
| Athira Pharma, Inc. | 125.46 Million USD | 95.2% |
| Vaccinex, Inc. | 23.45 Million USD | 74.325% |
| HCW Biologics Inc. | 21.02 Million USD | 71.361% |
| XOMA Corporation | 46.46 Million USD | 87.039% |
| Nektar Therapeutics | 190.9 Million USD | 96.845% |
| Arvinas, Inc. | 480 Million USD | 98.745% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -164.831% |
| Merus N.V. | 200.49 Million USD | 96.996% |
| Omega Therapeutics, Inc. | 103.35 Million USD | 94.173% |
| Quince Therapeutics, Inc. | 34.62 Million USD | 82.605% |
| Rezolute, Inc. | 70.38 Million USD | 91.444% |
| Clene Inc. | 41.07 Million USD | 85.338% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | 63.231% |
| BeyondSpring Inc. | 24.86 Million USD | 75.781% |
| Synlogic, Inc. | 58.53 Million USD | 89.711% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | 66.342% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -34.064% |
| Peak Bio, Inc. | 1249.13 USD | -482009.388% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | 90.037% |
| Krystal Biotech, Inc. | 160.42 Million USD | 96.246% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | 97.775% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | 98.27% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -179.227% |
| MannKind Corporation | 125.59 Million USD | 95.205% |
| Ikena Oncology, Inc. | 84.57 Million USD | 92.88% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | 37.575% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | 93.279% |
| Gossamer Bio, Inc. | 183.75 Million USD | 96.723% |
| CohBar, Inc. | 12.38 Million USD | 51.388% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | 88.128% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | 78.166% |
| Legend Biotech Corporation | 583.14 Million USD | 98.967% |
| Mural Oncology plc | 192.07 Million USD | 96.865% |
| Biora Therapeutics, Inc. | 67.14 Million USD | 91.031% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | 62.7% |
| Disc Medicine, Inc. | 91.12 Million USD | 93.391% |
| Champions Oncology, Inc. | 28.11 Million USD | 78.576% |
| REGENXBIO Inc. | 321.15 Million USD | 98.125% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -12.328% |
| Anavex Life Sciences Corp. | 55.75 Million USD | 89.199% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | 84.543% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | 94.734% |
| Vaxart, Inc. | 90.72 Million USD | 93.362% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | 29.317% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | 85.928% |
| Cellectis S.A. | 97.32 Million USD | 93.812% |
| Longeveron Inc. | 21.25 Million USD | 71.66% |
| Repare Therapeutics Inc. | 167.35 Million USD | 96.402% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 99.557% |
| Inozyme Pharma, Inc. | 75.64 Million USD | 92.039% |
| Revolution Medicines, Inc. | 498.76 Million USD | 98.793% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | 9.468% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | 86.299% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | 91.926% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | 91.352% |
| Anixa Biosciences, Inc. | 11.06 Million USD | 45.55% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 99.874% |
| Denali Therapeutics Inc. | 527.23 Million USD | 98.858% |
| Revelation Biosciences, Inc. | 8.65 Million USD | 30.433% |
| Veru Inc. | 101.34 Million USD | 94.058% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | 74.272% |
| Cingulate Inc. | 22.75 Million USD | 73.54% |
| Passage Bio, Inc. | 108.38 Million USD | 94.444% |
| Context Therapeutics Inc. | 25.07 Million USD | 75.981% |
| Exicure, Inc. | 14.07 Million USD | 57.217% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | 97.078% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | 86.092% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | 34.38% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | 97.615% |
| Nuvalent, Inc. | 149.49 Million USD | 95.972% |
| ABVC BioPharma, Inc. | 8.06 Million USD | 25.347% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | 94.19% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | 71.923% |
| OmniAb, Inc. | 83.89 Million USD | 92.822% |
| Anew Medical, Inc. | 1.3 Million USD | -362.945% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | 81.62% |
| Lipocine Inc. | 15.08 Million USD | 60.066% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | 91.21% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | 92.092% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | 85.062% |
| G1 Therapeutics, Inc. | 114.84 Million USD | 94.756% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | 73.096% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 99.093% |
| Ocugen, Inc. | 71.56 Million USD | 91.585% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | 93.584% |
| Q32 Bio Inc. | 92.68 Million USD | 93.502% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | 71.559% |
| Alumis Inc. Common Stock | 158.17 Million USD | 96.193% |
| Equillium, Inc. | 50.6 Million USD | 88.1% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | 90.35% |
| Coya Therapeutics, Inc. | 13.9 Million USD | 56.692% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | 68.078% |
| Galera Therapeutics, Inc. | 46.95 Million USD | 87.173% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 94.448% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | 51.406% |
| Dominari Holdings Inc. | 23.83 Million USD | 74.734% |
| Edesa Biotech, Inc. | 9.22 Million USD | 34.703% |
| vTv Therapeutics Inc. | 11.9 Million USD | 49.423% |
| Bio-Techne Corporation | 563.03 Million USD | 98.93% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 98.527% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | 97.759% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | 95.447% |
| Candel Therapeutics, Inc. | 14.41 Million USD | 58.211% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | 96.321% |
| Nkarta, Inc. | 131.65 Million USD | 95.426% |
| BioCardia, Inc. | 12.12 Million USD | 50.316% |
| Iterum Therapeutics plc | 47.46 Million USD | 87.313% |